¼±Åà - È»ìǥŰ/¿£ÅÍŰ
´Ý±â - ESC
KMLE °Ë»ö
°Ë»ö ¼³Á¤
¿Â¶óÀÎ ÀÇÇмÀû
ÀÇÇпë¾î »çÀü
ÀÇÇоà¾î
ÀÇÇлçÀü
ÇÑ¿µ/¿µÇÑ»çÀü
¿µ¿µ»çÀü
»çÀÌÆ® ¼Ò°³
Àç°Ë»ö
"life phase"¿¡ ´ëÇÑ KI ÀÇÇпë¾î ¼¼ºÎ °Ë»ö °á°úÀÔ´Ï´Ù
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
1
¿µ¹®
ÇѱÛ
biological half life
»ý¹°ÇÐÀû¹Ý°¨±â
effective half life
À¯È¿¹Ý°¨±â
elimination half-life
¼Ò½Ç¹Ý°¨±â
half-life; half-time
¹Ý°¨±â
life cycle
»ýȰȯ, »ýȰ ÁÖ±â
life threatening
»ý¸íÀ» À§ÇùÇÏ´Â
physical half-life
¹°¸®Àû ¹Ý°¨±â
3D phase contrast angiography
3Â÷¿øÀ§»ó´ëÁ¶ Ç÷°üÃÔ¿µ¼ú
arterial phase
µ¿¸Æ±â
bulk phase model
µ¢¾î¸®À§»ó¸ðÇü
equilibrium phase
ÆòÇü±â
gradient induced phase shift effect
°æ»çÀ¯µµ À§»óº¯À§È¿°ú
in phase
µ¿À§»ó
in-phase image
À§»ó³»¿µ»ó
intravoxel phase dispersion
º¹¼¿³»À§»óÈ®»ê
´ÙÀ½
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
1
¿µ¹®
ÇѱÛ
ÅëÇÕ°Ë»ö ¿Ï·á
´ÙÀ½